Faden Lab receives funding to conduct immunogenomic studies in collaboration with Bristol Myers Squibb clinical trial

September 27, 2020

The Faden lab, in collaboration with Moshe Sade-Feldman, PhD and Shannon Stott, PhD will investigate the impact of the addition of Motolimod, a TLR8 agonist, to anti-PD-L1 therapy. To do so, the team, with funding from Bristol Myers Squibb, will utilize samples collection from a study entitled: A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN).